PNB-081
Obesity
PNB-081 for Obesity
- Molecule
- PNB-081
- Development status
- IND ready
- Therapeutic area
- Metabolic Diseases
- Biological action
- CCK-mediated reduction of food intake
- Therapeutic target
- Cholecystokinin Receptors A, CCK1
- Therapeutic indication
- Weight reduction
- Secondary indications
- Second generation antidiabetic T2D with reduction of food intake
Stage of development
-
- Molecule
- PNB-081
- Indication
- Obesity
- Biological action
- CCK-mediated reduction of food intake
- Status
- IND ready
- Background about target
In line with the increase in Obesity Type 2 Diabetes (T2D) is rising and T1 Diabetes is associated with immune dysregulation and immune attack on the beta cell with the known loss of insulin production. PNB-081 is developed from PNB-001, but its action is not limited to glucose lowering activity and is efficient in lowering food intake in rats.
CCK was known as incretin, most accurately as non-classical incretin in addition to GIP (gastrin inhibiting peptide, = later termed glucose dependent insulinotropic polypeptide) and GLP1.
- Preclinical studies:
In the glucose tolerance test a 2 mg/kg dose reduced the blood glucose level when required. In the feeding experiments using metabolic cages, the food intake in rats was reduced from day 2 onwards and the magnitude of the effect was up to 50% reduction of food intake, measured in a group of 6 rats.
Previously the prevention of opiate tolerance was seen in PNB-081 orally administered at 1 mg/kg in mice and 4 mg/kg of morphine. These effects of morphine addiction as well as food addiction may be attributed to the same underlying cause, as sort of food, sugar and Opiate Addiction.
In addition, PNB-081 was also effective in preclinical models of Pancreatitis, depression and anxiety showing the link metabolism and CNS effects.
- Preclinical development studies:
PNB-081 is in terms of binding profile equivalent to devazepide, but has excellent pharmacokinetics with >40% oral bioavailability, as well as very high membrane penetration. Other studies, including CaCo2 permeability and plasma protein binding demonstrated favorable druggable properties of PNB-081.
- Intellectual property:
Since PNB-081 belongs to the same class as PNB-028 or PNB-001, its chemical structure is also well protected until 2037 (including 5 years of extension) in most of the countries around the World.
About PNB-081
Preclinical completed · IND ready
A closely related molecule addressing Obesity at low doses and, at higher doses, acting as an opiate-sparing agent. It may also substitute for PNB-028 in Pancreatitis.
PNB-081 full profileInterested in a programme?
PNB Vesper welcomes discussions on clinical development, licensing, co-development and investment for any molecule in the pipeline.
